A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or esters of amides thereof, which is an inhibitor of monocyte chemoattractant protein-1 and wherein A and B together form an optionally substituted 5-membered aromatic ring which includes at least one heteroatom; X is CH2 or SO2; R<1> is an optionally substituted aryl or heteroaryl ring; R<2> is selected from a range of organic groups including carboxy, and R<3> is hydrogen, or a range of organic groups; in combination with a pharmaceutically acceptable carrier. Certain compounds of formula (I) are novel and these form a further aspect of the invention.
